Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from proliferating cell nuclear antigen

[1]  V. Apostolopoulos.  Peptide-based vaccines for cancer: are we choosing the right peptides? , 2009, Expert review of vaccines.

[2]  W. Kast,et al.  Peptide-based vaccines for cancer: realizing their potential , 2008, Expert review of vaccines.

[3]  Morten Nielsen,et al.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..

[4]  V. Brusic,et al.  Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research , 2008, BMC Immunology.

[5]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[6]  Leonard Moise,et al.  Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.

[7]  Anthony Kusalik,et al.  Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools , 2007, Immunome research.

[8]  Marij J P Welters,et al.  Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. , 2006, Advanced drug delivery reviews.

[9]  Markus Weininger,et al.  Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin , 2006, Cancer Immunology, Immunotherapy.

[10]  V. Apostolopoulos,et al.  Design of peptide-based vaccines for cancer. , 2006, Current medicinal chemistry.

[11]  C. Klade,et al.  Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. , 2006, Vaccine.

[12]  Vladimir Brusic,et al.  Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications. , 2004, Methods.

[13]  H. Yamana,et al.  Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer , 2004, Cancer science.

[14]  S. Markovic,et al.  Challenges in the development of effective peptide vaccines for cancer. , 2002, Mayo Clinic proceedings.

[15]  J. Becker,et al.  Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. , 2001, Cancer research.

[16]  M. C. Parkinson,et al.  Prognostic markers in clinically localised prostate cancer. , 1999, International journal of oncology.

[17]  J. C. Lee,et al.  Growth kinetics of colorectal adenoma-carcinoma sequence: an immunohistochemical study of proliferating cell nuclear antigen expression. , 1996, Human pathology.

[18]  K. Kim,et al.  Selection of peptides that bind to the HLA-A2.1 molecule by molecular modelling. , 1996, Molecular immunology.

[19]  S. H. van der Burg,et al.  Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes , 1993, European journal of immunology.

[20]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[21]  Kun Yu,et al.  Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study , 2002, Molecular medicine.